ELIC Stock Overview
A clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Elicera Therapeutics AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.74 |
| 52 Week High | SEK 5.80 |
| 52 Week Low | SEK 0.85 |
| Beta | -0.42 |
| 11 Month Change | -3.61% |
| 3 Month Change | -17.38% |
| 1 Year Change | -64.59% |
| 33 Year Change | -67.57% |
| 5 Year Change | n/a |
| Change since IPO | -72.02% |
Recent News & Updates
Recent updates
Shareholder Returns
| ELIC | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -7.5% | -0.4% | 0.1% |
| 1Y | -64.6% | 15.1% | 11.8% |
Return vs Industry: ELIC underperformed the Swedish Biotechs industry which returned 14.3% over the past year.
Return vs Market: ELIC underperformed the Swedish Market which returned 11.8% over the past year.
Price Volatility
| ELIC volatility | |
|---|---|
| ELIC Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 11.2% |
| 10% least volatile stocks in SE Market | 3.3% |
Stable Share Price: ELIC's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: ELIC's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 2 | Jamal El-Mosleh | www.elicera.com |
Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors.
Elicera Therapeutics AB (publ) Fundamentals Summary
| ELIC fundamental statistics | |
|---|---|
| Market cap | SEK 60.89m |
| Earnings (TTM) | -SEK 20.79m |
| Revenue (TTM) | SEK 12.07m |
5.0x
P/S Ratio-2.9x
P/E RatioIs ELIC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ELIC income statement (TTM) | |
|---|---|
| Revenue | SEK 12.07m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 12.07m |
| Other Expenses | SEK 32.86m |
| Earnings | -SEK 20.79m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 29, 2024
| Earnings per share (EPS) | -0.59 |
| Gross Margin | 100.00% |
| Net Profit Margin | -172.21% |
| Debt/Equity Ratio | 0% |
How did ELIC perform over the long term?
See historical performance and comparison